Fennec Pharmaceuticals Inc. (FRX.TO)
| Previous Close | 7.27 |
| Open | 7.27 |
| Bid | 7.07 x 0 |
| Ask | 7.52 x 0 |
| Day's Range | 7.27 - 7.27 |
| 52 Week Range | 4.95 - 13.25 |
| Volume | |
| Avg. Volume | 239 |
| Market Cap | 189.306M |
| Beta (5Y Monthly) | -0.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.82 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 20, 2022 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 14, 2022. Detailed results of the vote for the election of directors are set out below:
- GlobeNewswire
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences. Presentation Details: Even
- GlobeNewswire
Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $18.3 Million in Cash and $5 Million of Funded Debt ~ RESEARCH TRIANGLE PARK, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM
